TC
PVLA

TFS Capital’s Palvella Therapeutics PVLA Stock Holding History

TFS Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-685
Closed -$277K – 369
2017
Q2 		$277K Buy
685
+276
+67% +$80.7K 0.11% 364
2017
Q1 		$85K Buy
+409
New +$72.4K 0.03% 603
2016
Q3 		– Sell
-130
Closed -$17K – 1013
2016
Q2 		$17K Buy
+130
New +$19.9K ﹤0.01% 940
2016
Q1 		– Sell
-295
Closed -$54K – 1108
2015
Q4 		$54K Sell
295
-262
-47% -$44K 0.01% 699
2015
Q3 		$82K Buy
+557
New +$124K 0.01% 816

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFS Capital's PVLA Position: Q3 2017 in Review

TFS Capital sold out of Palvella Therapeutics (PVLA) in Q3 2017, closing a stake of 685 shares — an estimated $277K sold.

TFS Capital first reported a position in PVLA in Q3 2015 and held it in 5 quarters. The position peaked at $277K in Q2 2017. 66 funds tracked by Wall St. Rank hold PVLA as of Q3 2017.

  • TFS Capital reported no remaining Palvella Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 685 Palvella Therapeutics shares in Q3 2017, an estimated $277K.
  • TFS Capital first reported a position in Palvella Therapeutics in Q3 2015 and held it in 5 quarters.
  • TFS Capital's Palvella Therapeutics position peaked at $277K in Q2 2017.
  • 66 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.